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Endocrine disrupting chemicals (EDCs) are chemicals that have the capacity to interfere with normal endocrine systems. Two
EDCs, bisphenol A (BPA) and triclosan (TCS), are mass-produced and widespread. They both have estrogenic properties and
similar chemical structures and pharmacokinetic features and have been detected in human fluids and tissues. Clinical evidence
has suggested a positive association between BPA exposure and implantation failure in IVF patients. Studies in mouse models have
suggested that preimplantation exposure to BPA and TCS can lead to implantation failure. This paper reviews the relationship
between preimplantation exposure to BPA and TCS and implantation failure and discusses the remaining problems and possible
solutions.
1. Introduction
During the last few decades, the incidence of human infer-
tility has significantly increased in many countries, such as
the United States and China [1–5]. The rate of this increase
is too rapid to be explained by genetic mutations. More
than 10% of infertile couples suffer from infertility of an
unexplained nature [6]. The women in these couples have
normal ovulatory cycles and hormonal profiles and no organ
pathologies. Their partners show no evidence of semen
quality problems. In the meantime, the production of many
artificial chemicals such as plastics has been increased [7].
Some chemicals which have been widely used for decades
have recently been found to have the ability to disrupt
endocrine function in humans. They are called endocrine
disrupting chemicals (EDCs). Bisphenol A (BPA) and tri-
closan (TCS) are EDCs with similar chemical structures to
17𝛽-estradiol [8] (Figure 1). They have recently been noticed
due to their ubiquitous presence in the environment and in
human fluids and tissues [9–23]. BPA is the monomer used
in the production of polycarbonate plastics and some epoxy
resins. It is one of the most-produced chemicals worldwide,
with over six billion pounds produced each year [21]. TCS
is an antimicrobial additive used in many personal care and
household products.
Many studies have suggested that BPA exposure is asso-
ciated with female infertility [15–17]. However, the associa-
tion between TCS exposure and female infertility remains
unknown. Mice have been used as an animal model to study
the association between the exposure to these two chemicals
and infertility [24–28].
Subtle changes in estrogen levels can lead to implantation
failure in humans and mice [29, 30]. BPA and TCS have
estrogenic activity in vitro and in vivo [21, 31]. BPA binds
to both ER𝛼 and ER𝛽 [32–35]. Both BPA and TCS have
many biological effects mediated via estrogen receptors [36–
39]. Thus, BPA and TCS may cause implantation failure due
to their ability to mimic estrogen in humans [40–42]. In
human beings, from oocyte maturation to implantation, the
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Figure 1: Chemical structures of BPA, TCS, and 17𝛽-estradiol.
dramatically. The levels of sex hormones, such as estrogen,
progesterone, and androgen, and their receptors also change
dramatically. Thus, the sensitivity of the female reproductive
system to BPA and TCS may vary depending on the time of
exposure. It has been reported that, in mice, preimplantation
exposure to the same amount of BPA or TCS on gestational
day 2/3 is more potent to induce embryo implantation failure
than exposure on gestational day 0/1 [27, 28]. Thus, in
mice, gestational day 2-3 may be a sensitive window for
BPA and TCS. Exposure to these two endocrine disruptors
during a sensitive windowmight lead to implantation failure.
However, in human beings, the sensitive window for these
EDCs still needs further investigation.
2. Exposure and Detection of
BPA and TCS in Humans
2.1. The Route and Amount of Exposure to BPA and TCS in
Humans. There is a trend of increased exposure to endocrine
disrupting chemicals, including BPA and TCS. In 2008, it
was reported that daily exposure of BPA to humans is below
0.1 𝜇g/kg/day for the majority of the population [43]. In 2011,
Taylor et al. suggested that total daily human exposure of BPA
is via multiple routes and is much higher than previously
assumed based on animal studies and pharmacokinetic fea-
tures of BPA in human and animal [44]. Recently, Lassen et
al. [45] reported that the median daily intake of BPA among
33 Danish men is approximately 27 ng/kg/day.
Although BPA and TCS can be absorbed orally, dermally,
and by inhalation [46], the majority of absorption occurs
via ingestion. It is estimated that 90–99% of BPA exposure
in adults and children is from food [47–49]. Allmyr et
al. [50] suggested that oral care products are probably the
most important means of exposure to TCS in adults because
brushing teeth with TCS-containing toothpaste has been
shown to result in a large and rapid uptake of TCS. However,
the percentage of TCS ingested orally in relation to total TCS
absorption is not known.
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Table 1: The distribution and amount of BPA and TCS in human tissue.
Chemical Tissue type Concentration References
BPA
Serum (adult) ∼1-2 ng/mL [22, 81]
Serum (fetal) ∼1-2 ng/mL [22]
Breast milk 0.61 ± 0.20 ng/mL [82]
Colostrum 3.41 ± 0.13 ng/mL [83]
Follicular fluid ∼1-2 ng/mL [22]
Amniotic fluid (full term) ∼1-2 ng/mL [22]
Amniotic fluid (15–18-week gestation) 8.3 ± 8.7 ng/mL [22]
Urine 2.75–3.3 𝜇g/g creatinine (∼3.00 ng/mL) [84, 85]
Brain 0.91 ng/g [10]
Adipose tissue 3.78–5.83 ng/g [10, 86]
Liver 1.48 ng/g [10]
TCS
Serum 4.1–19 ng/g [50]
Breast milk 1.3 ± 2.7 ng/g fresh weight [87]
Urine 3.55 𝜇g/g creatinine (3.77 ng/mL) [84]
Adipose tissue 0.61 ng/g [10]
Liver 3.14 ng/g [10]
Rodricks et al. [51] estimated the amount of human
daily exposure to TCS from two approaches. One approach
is based on the estimation of the combination of daily
intake products, and the other is based on biomonitoring
data from human volunteers. The total intake of TCS per
day from the consumer products evaluated were 0.047,
0.065, and 0.073mg/kg/day for men, women, and children,
respectively [51].The daily TCS intake estimates based on the
50th percentile urinary concentrations of TCS reported in
the NHANES (National Health and Nutrition Examination
Survey) 2003-2004 were approximately 0.0002, 0.0002, and
0.0001mg/kg/day formen, women, and children, respectively
[51]. The estimates based on the 95th percentile urinary
concentrations of TCS were approximately 0.009, 0.007,
and 0.004mg/kg/day [51]. The estimated exposure level of
TCS based on biomonitoring data is much higher than the
product-based TCS intake estimates and suggests that actual
TCS intakes are lower than the product-based estimates.
People living in different regions or having different living
habits are probably exposed to different amounts of these
two EDCs. And the human exposure level of BPA and TCS
remains unclear and needs further investigation.
2.2. Distribution and Amount of TCS and BPA in Human
Tissue. BPA and TCS have been detected in the blood, breast
milk, urine, adipose tissue, liver, and brain of most human
volunteers [9–21]. BPA has also been detected in human
amniotic fluid and follicular fluid [22, 23]. The distribution
and amount of BPA and TCS in the human body are
listed in Table 1. It is interesting that BPA has an ∼5-fold
higher concentration at 15–18-week gestation, which must be
considered in evaluating the potential for human exposure to
BPA [22]. The concentrations of BPA in serum, breast milk,
follicular fluid, amniotic fluid (full term), and urine are very
close, suggesting that BPA is distributed evenly in human
fluids. The distribution and amount of BPA and samples
suggest a profile of ubiquitous presentation in human body.
3. Pharmacokinetics of BPA and TCS
3.1. BPA. Völkel et al. [52] administered 5mg radioactive
BPA/person (54–90 ug/kg body weight) and reported that
this BPA was completely eliminated from the body within
24 h. Maximum plasma concentrations were reached 80min
after dosing and rapidly declined for the next 6 h. BPA is
only detected in its glucuronidated form and not as free
BPA. This study indicates that BPA was absorbed from the
gastrointestinal tract quickly, conjugatedwith glucuronic acid
in the liver, and BPA-glucuronide was rapidly filtered from
the blood by the kidneys and excreted in the urine [52]. Acute
studies in both mice and humans indicate rapid metabolism
and clearance of BPA [44, 52, 53].
3.2. TCS. The absorption of TCS following oral administra-
tion in both humans andmice is rapid and efficient [51].Max-
imum plasma concentrations were achieved 1 to 3 h following
administration in humans and 1 to 4 h in mice, respectively
[51, 54]. In humans, TCS does not accumulate in the blood
[55]. Nearly all of the TCS absorbed is metabolized to sulfate
and glucuronide conjugates in both humans andmice [51, 56,
57]. In humans, about 80–85% of the administered dose in
volunteers is excreted in the urine (71–80%) or feces (5–7%) in
the form of conjugated metabolite, and the elimination half-
life of TCS is estimated to be approximately 10 to 20 h [51, 54].
Most of the absorbed TCS can be excreted from the human
body less than 24 h after exposure [54].
In short, the pharmacokinetic features of TCS are very
similar to BPA in both humans andmice. In both humans and
mice, TCS can be rapidly and nearly completely absorbed,
metabolized to glucuronide and sulfate conjugates, and
excreted.
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4. Preimplantation Exposure to BPA and TCS
Can Cause Implantation Failure
Accumulating evidence suggests that there is an association
between women’s exposure to BPA and female infertility.
Moreover, animalmodel studies have suggested that exposure
to BPA, TCS, or both BPA and TCS during the preimplanta-
tion period could lead to implantation failure in mice.
4.1. Clinical Studies. In 2005, Sugiura-Ogasawara et al. [17]
reported that BPA is associated with recurrent miscarriage
in humans. Recently, Ehrlich et al. [15] reported a significant
linear dose-response association between increased urinary
BPA concentrations and a decreased number of oocytes
(overall and mature), a decreased number of normally fer-
tilized oocytes, and decreased peak serum estradiol levels.
Themean number of oocytes and normally fertilized oocytes
decreased by 24 and 27%, respectively, for the highest versus
the lowest quartile of urinary BPA (trend test 𝑃 < 0.001
and 0.002, resp.). Women with urinary BPA above the lowest
quartile had decreased blastocyst formation (trend test 𝑃 =
0.08). Ehrlich et al. [16] also claimed a positive linear dose-
response association between BPA urinary concentrations
and implantation failure.
The correlation between the concentration of TCS in
pregnant women and female infertility remains unclear due
to a lack of investigation. However, the similarity of the
distribution, chemical structures, and estrogenic activity of
BPA and TCS suggests the possible involvement of TCS in
implantation failure.
4.2. Animal Studies. Implantation failure could be caused by
the embryo itself, inadequate uterine receptivity, or defects in
communication between the embryo and the endometrium.
It is generally assumed that the embryo itself is probably only
responsible for one-third of IVF failures, and the other two-
thirds of implantation failures occur due to impaired uterine
receptivity or defects in embryo-endometrium communica-
tion [58–60]. Animal models have been used to investigate
the effect of preimplantation exposure of BPA and TCS on
implantation.
Crawford and deCatanzaro [28] studied the impact of
preimplantation exposure to BPA, TCS, and BPA and TCS
on implantation rates in mice. They found that exposure
to TCS on the level of 523/785mg/kg/day on gestational
days (GD) 1–3 could significantly reduce implantation rates
by 30%/40% [28]. They also found that although doses of
4mg BPA (122mg/kg) and 9mg triclosan (262mg/kg) on
GD 1–3 were individually ineffective, in combination they
reduced the number of implantation sites and also increased
gestation length [28]. Xiao et al. [24] showed that preimplan-
tation exposure to 100mg/kg/day BPA on gestational days
0.5–3.5 can reduce implantation rates to zero by affecting
uterine receptivity, embryo transport, and preimplantation
embryo development in mice. Berger et al. [25] reported
that preimplantation exposure to 200/300mg/kg/day BPA
on gestational days 1–4 can reduce implantation sites by
70%/100%.
Takai et al. [61] showed that, at 100 uM, BPA could inhibit
the development of preimplantation embryos in vitro. At
lower, more environmentally relevant concentrations (1 nM
and 3 nM), BPA has stimulatory effects on embryo develop-
ment in mice.
4.3. Possible Mechanisms. Uterine receptivity and embryo
development are both critical for successful implantation.
Coordinated actions of progesterone and estrogen play a crit-
ical role in creating a receptive uterine environment, embryo
development, and embryo migration through the oviduct
[62, 63]. Estrogen and progesterone actions are critical in
the regulation of uterine cell proliferation, establishing a
window of receptivity for blastocyst implantation [64, 65]. In
mice, this window is very narrow and sensitive to changes in
steroid levels [29, 62]. Small increases in estradiol levels can
alter uterine PR (progesterone receptor) and gene expression,
causing the uterus to enter a refractory state and thereby
decreasing the probability of successful implantation [29].
Kim et al. [66] claimed that, through nuclear ER-dependent
ERK1/2 phosphorylation, both E2 and BPA can rapidly
and transiently induce Egr1 which may be important for
embryo implantation and decidualization in mouse uterus.
Recently,Mannelli et al. [67] reported that BPA perturbed the
expression of ER𝛼, ER𝛽, PRA, PRB, and hCG/LH-R, reduced
themRNA transcription of dPRL, and stimulated secretion of
MIF in human endometrial stromal cells in vitro.
Several studies have shown that BPA can impair the
development of mouse embryos and that this effect can be
counteracted by Tamoxifen (an estrogen receptormodulator)
[24, 61, 68]. Thus, the impairment of BPA on the embryo is
probably mediated by the estrogen receptor.
BPA, TCS, and 17𝛽-estradiol have similar chemical struc-
tures and they are all fat-soluble chemicals. BPA and TCS
both have estrogenic activity, share similar pharmacokinetic
features, and can be detected in human fluids and tissues.
Evidence from clinical studies and animal models supports
the assumption that preimplantation exposure to BPA and
TCS could lead to implantation failure in humans.
In addition, preimplantation exposure to BPA can non-
monotonically change the expression of the ER𝛼 (estrogen
receptor 𝛼) and PR (progesterone receptor) in the uterus of
mice [25]. Thus it seems that BPA might interfere with the
coordinated actions of progesterone and estrogen and impair
the receptivity of the uterus and embryomigration. Xiao et al.
[24] reported that preimplantation exposure to BPA affects
embryo transport, preimplantation embryo development,
and uterine receptivity in mice.
BPA also can increase the luminal area and luminal cell
height of the mouse uterus on gestational day 6 following
subcutaneous injections of BPA on days 1–4 of gestation
[25]. These morphological changes in the uterus could have
implications for the success of blastocyst implantation.
Varayoud et al. [69] reported that neonatal exposure to
BPA alters rat uterine HOXa10 and its downstream gene
expression and reduces the number of implantation sites
compared to the control group. Bromer et al. [70] claimed that
BPA exposure in utero on gestational days 9–16 (after implan-
tation and in the middle of the pregnancy) can upregulate
















Figure 2: Possible mechanism by which BPA and TCS may affect
embryo implantation.
the expression of HOXa10 in the uterus of female offspring
in mice. However, whether preimplantation exposure to BPA
affects the expression of HOXa10 and its downstream genes
has not been investigated.
Some studies have suggested that exposure to BPA could
affect the meiotic maturation of oocytes in humans and mice
[71–76].
Crawford and deCatanzaro [28] suggested that preim-
plantation exposure to TCS can also cause implantation
failure in mice and that TCS can act in conjunction with
BPA. However, the mechanism of this implantation failure in
humans and mice is still unknown. The possible mechanism
by which the two chemicals may affect embryo implantation
is illustrated in Figure 2.
5. Summary and Suggestions for
Further Studies
In the clinic, fertilization can only be confirmed afterwards.
There is no way to detect embryo implantation failure in the
clinic except for patients undergoing in vitro fertilization.
The most common way to diagnose pregnancy is by testing
human chorionic gonadotrophin (HCG) in urine samples.
However, HCG is secreted by the syncytiotrophoblast and is
detectable in maternal blood two days after the implantation
of the embryo [77]. Thus, it is possible that many women
did not know that they had a fertilized embryo which failed
to implant into their endometrium because no HCG was
secreted. Even if there was vaginal bleeding and they went to
see a gynecologist, it will only be seen as ovulation bleeding
which is very common in the clinic. Most of the time, when
a woman wants to know if she is pregnant she will do a
urine pregnancy test. However, a detectable level of HCG in
the urine requires the embryo to survive for at least a week
after implantation. Since BPA and TCS can be absorbed and
excreted quickly and do not accumulate in the human body
[44, 51–53], a change in habits like starting or stopping using
TCS-containing toothpaste or using plastic food containers
can cause a fluctuation in the levels of these two chemicals
in the human body. This means that if the exposure ceased
during the sensitive time frame—for example, the woman
has used up her TCS-containing toothpaste and bought some
new TCS-free toothpaste or lost her plastic bottles which leak
BPA—she could have a relatively low level of TCS and BPA
in her body during this time and become pregnant. In the
clinic, a woman cannot be defined as infertile unless she has
attempted unprotected coitus for at least one year without
becoming pregnant. This means that perhaps BPA and TCS
have caused more miscarriages than we have realized.
However, the most sensitive time for BPA and TCS
to influence implantation remains unknown. Although the
preimplantation period might be a sensitive time frame for
BPA and TCS exposure, it might not be the most sensitive
and important one.
The procedure of in vitro fertilization and embryo trans-
fer (IVF/ET) has provided some possible ways to identify the
most dangerous time frame for TCS and BPA exposure in
humans.Only in those patientswouldwe know the exact time
of fertilization, the condition of the oocyte prefertilization,
and the embryo’s preimplantation.
Recently, Ehrlich et al. [15, 16] studied the association
between BPA exposure levels and the clinical outcomes of
IVF patients as mentioned above. However, their study did
not measure the exposure level of TCS in those patients
or the chromosomal condition of the oocytes before fertil-
ization using techniques such as biopsy of their first polar
body or the discarded GV (germinal vesicle) oocytes (i.e.,
immature oocytes). Oocytes with meiotic abnormalities can
look normal and even become fertilized, but they lead to a
low fertilization rate or a low implantation rate if they are
fertilized [78, 79].
Many studies have investigated the association between
BPA exposure and clinical outcomes in IVF patients [14–
16, 18]. However, the menstrual cycles of IVF patients are
not natural but are altered using hormones to obtain more
ova and the optimal endometrium state during embryo
transfer. Since it is likely that BPA and TCS act through
estrogen receptors, it is best to study their effect under natural
conditions where the status of estrogen receptors and the
amount of estrogen in vivo are less affected by exogenous
hormones. For example, one could conduct the study in IVF
patients undergoing natural cycles. Since only patients with
stable menstrual cycles would be included in this procedure,
the samples may be more monotonous. Also, most of the
animal studies have used the subcutaneous route for exposure
[25, 27, 28, 69]. However, human exposure to BPA and TCS
is mainly orally. So either gavage or food and drink might be
a better exposure procedure for animal models.
It is not easy to maintain low TCS and BPA exposure
levels due to their widespread existence. And recently it has
been reported that BPA-free plastic products also release
other chemicals with estrogenic activity [80]. Fortunately, the
pharmacokinetic features of these two chemicals suggest that
the fertility rate of women could probably be raised just by
minimizing contact with BPA- and TCS-containing products
during sensitive time frames such as the preimplantation
period. However, the other part of reproduction, including
the period of the second meiosis of the oocyte, cannot be
6 BioMed Research International
excluded. If we could determine the most sensitive time
frame for these two chemicals, we might not need to find a
counteractive drug.
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